GeneChem Management

GeneChem is a private equity and venture capital firm specializing in growth capital, seed, and startup financings to later stage mezzanine rounds and private placements in publicly listed companies. The firm typically invests in the genomics industries with a focus on companies involved in gene discovery; functional genomics; bio-informatics; proteomics; gene therapy; biotechnology; developing therapeutics for proliferative diseases including cancer, infectious diseases, inflammation, and diabetes; and developing therapeutics targeting age-related diseases. It primarily invests in Canada, the United States, and Europe. The firm prefers to have a Board seat and invests in the form of common stock, convertible preferred stock, and convertible debentures or notes with warrants. It intends to undertake the role of lead investor where possible. In early stage deals, the firm may be the sole investor but it generally prefers to take part in syndicated deals as lead or follower. GeneChem was founded in 1997 and is based in Montreal, Canada.

Elizabeth Douville

General Partner

Inès Holzbaur

General Partner

Louis Lacasse

General Partner

Martial Lacroix

General Partner

Maxime Pesant

VP, Finance

31 past transactions

MethylGene

Venture Round in 1999
MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for serious fungal infections which has completed Phase I clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is currently in a Phase II trial in refractory or relapsed follicular lymphoma. Mocetinostat is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent for neurodegenerative diseases has successfully completed Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry.

Copernicus Therapeutics

Venture Round in 1999
Copernicus Therapeutics, Inc. (CTI) is a clinical stage biopharmaceutical company and a leader in the emerging field of precision medicine and gene therapy. Through their proprietary, non-viral, nucleic acid nanoparticle platform, they are able to achieve robust gene transfer in several tissues without the immune response and limited treatment window of AAV.

Chromos Molecular System

Venture Round in 2005
Chromos Molecular System is an online community for aestheticians, laser, and medical professionals. Chromos is the Greek word for color – and as we know, without light there is no color. Lorenzo Kunze’s 40 years in the medical and aesthetic field provides him the ability and experience to provide a pure and guiding light to medical and aesthetic professionals around the world.

Aegera Therapeutics

Venture Round in 2002
Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials.

Viron Therapeutics

Series A in 2000
Viron Therapeutics is a clinical stage biopharmaceutical company pioneering the development of viral proteins to treat and prevent human inflammatory disorders. Viral proteins represent a revolutionary new class of drugs. By harnessing the evolutionary power of viruses and other pathogens to evade the human body's protective inflammatory response, Viron is able to identify and develop powerful protein therapeutics that have distinct advantages in potency and efficacy over conventional drug therapy. Viron is the first company to successfully advance a viral protein drug into human testing.

Cytochroma

Series A in 1999
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.

Ambit Biosciences

Series C in 2005
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Idun Handel & Industri AB

Series A in 2002
IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.

Salmedix Inc

Series B in 2002
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

Cytochroma

Series C in 2007
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.

LymphoSign

Series A in 2003
LymphoSign is a pharmaceutical company that is focused on the development of drugs for blood cancers. LymphoSign was acquired by Aegera Therapeutics in August 2007. LymphoSign was founded in 2000 and is based in Markham, Canada.

Ambit Biosciences

Series D in 2007
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.
Lexicon Pharmaceuticals, Inc. (formerly Lexicon Genetic) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.

Osprey Pharmaceuticals USA

Venture Round in 2007
Osprey Pharmaceuticals USA, Inc. develops protein therapeutics for the treatment of inflammatory and immune diseases. Its pipeline of fusion protein therapeutics includes leukocyte population modulators that target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases. The company's lead candidate CCL2-LPM targets the CCR2 chemokine receptor expressed by pathologically activated leukocytes is for the treatment of IgA nephropathy, an inflammatory kidney disease. Osprey Pharmaceuticals USA, Inc. was founded in 2008 and is based in San Francisco, California.

Copernicus Therapeutics

Venture Round in 2002
Copernicus Therapeutics, Inc. (CTI) is a clinical stage biopharmaceutical company and a leader in the emerging field of precision medicine and gene therapy. Through their proprietary, non-viral, nucleic acid nanoparticle platform, they are able to achieve robust gene transfer in several tissues without the immune response and limited treatment window of AAV.

Xanthus Pharmaceuticals

Series B in 2003
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.

Ore Pharmaceuticals

Venture Round in 1997
Gene Logic is a leading integrated genomics company providing comprehensive Genomic Reference Databases and GLP compliant Microarray Services. Over 2/3rd of the top 25 Pharma companies, leading research institutes and emerging biotech companies worldwide have chosen us as their preferred genomics partner and utilize our expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets & biomarkers.

Elitra Pharmaceuticals

Venture Round in 2000
Elitra Pharmaceuticals in San Diego, CA is a private company categorized under Pharmaceutical Preparations. It was established in 1997 and incorporated in California.

NewBiotics

Series E in 2004
NewBiotics transforms drug resistances into therapeutic advantages. It focuses on the discovery and development of drug molecules that leverage the cycle of drug resistance in both cancer and infectious diseases. NewBiotics is a U.S.-based company that was founded in 1997 and the company was acquired by Celmed Biosciences on June 7, 2004.

The Medicines Company

Venture Round in 1999
The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company's pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.

GeneFormatics

Venture Round in 2001
GeneFormatics is a biotechnology company specializing in structural proteomics.
Osprey Pharmaceuticals USA, Inc. develops protein therapeutics for the treatment of inflammatory and immune diseases. Its pipeline of fusion protein therapeutics includes leukocyte population modulators that target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases. The company's lead candidate CCL2-LPM targets the CCR2 chemokine receptor expressed by pathologically activated leukocytes is for the treatment of IgA nephropathy, an inflammatory kidney disease. Osprey Pharmaceuticals USA, Inc. was founded in 2008 and is based in San Francisco, California.
Interomex Biopharmaceuticals Inc. is dedicated to the identification of novel biological targets in key cellular processes with the aim of discovering lead compounds for the treatment of disease. The company’s proprietary Repressed Trans-activator (RTATM) technology can be used to detect protein-protein interactions between a host and an infectious agent, as well as within cells in normal and diseased states. A particular advantage of RTATM is its ability to detect the interactions of transcription transactivator proteins, which are key control points in viral infections and cell activation.

Cytochroma

Series B in 2001
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.

Message Pharmaceuticals

Venture Round in 1999
Message Pharmaceuticals

Ceptyr

Venture Round in 1999
Ceptyr, Inc was founded to focus on developing drugs against protein tyrosine phosphatases (PTPs), a largely unexplored niche in pharmaceutical development.

Cytochroma

Series B in 2001
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.

NewBiotics

Series C in 2001
NewBiotics transforms drug resistances into therapeutic advantages. It focuses on the discovery and development of drug molecules that leverage the cycle of drug resistance in both cancer and infectious diseases. NewBiotics is a U.S.-based company that was founded in 1997 and the company was acquired by Celmed Biosciences on June 7, 2004.

Xanthus Pharmaceuticals

Series B in 2006
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.

Novalon Pharmaceutical

Venture Round in 2000
Developer of drugs for medical needs. Company develops novel pharmaceuticals through the company's technology access programs and therapeutic programs.